Literature DB >> 16786512

Identification of a novel mutation of SH3BP2 in cherubism and demonstration that SH3BP2 mutations lead to increased NFAT activation.

Steven A Lietman1, Natasha Kalinchinko, Xichao Deng, Ronald Kohanski, Michael A Levine.   

Abstract

We describe a novel missense mutation (Aspartic acid to Asparagine, p.D419N (g.1371G>A, c.1255G>A) within exon 9 of SH3BP2 in a patient with cherubism, an autosomal dominant syndrome characterized by excessive osteoclastic bone resorption of the jaw. Two siblings and the father were carriers but lacked phenotypic features. Transient expression of p.D419N (c.1255G>A), as well as three previously described exon 9 mutations from cherubism patients (p.R415Q (c.1244G>A), p.D420E (c.1259G>A), and p.P418R (c.1253C>G)) increased activity of NFAT (nuclear factor of activated T-cells), an osteoclastogenic mediator, indicating that cherubism results from gain of function mutations in SH3BP2.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16786512     DOI: 10.1002/humu.9433

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  13 in total

1.  SH3BP2 mutations potentiate osteoclastogenesis via PLCγ.

Authors:  Steven A Lietman; Lihong Yin; Michael A Levine
Journal:  J Orthop Res       Date:  2010-11       Impact factor: 3.494

2.  Identical Mutation in SH3BP2 Gene Causes Clinical Phenotypes with Different Severity in Mother and Daughter - Case Report.

Authors:  L Preda; O Dinca; A Bucur; C Dragomir; E Severin
Journal:  Mol Syndromol       Date:  2010-06-09

3.  Cloning and characterization of the human SH3BP2 promoter.

Authors:  Chun Fan; Robert J Gaivin; Thomas A Marth; Belinda Willard; Michael A Levine; Steven A Lietman
Journal:  Biochem Biophys Res Commun       Date:  2012-07-17       Impact factor: 3.575

4.  Decreased SH3BP2 inhibits osteoclast differentiation and function.

Authors:  Teruya Kawamoto; Chun Fan; Robert J Gaivin; Michael A Levine; Steven A Lietman
Journal:  J Orthop Res       Date:  2011-03-29       Impact factor: 3.494

5.  Loss of Tankyrase-mediated destruction of 3BP2 is the underlying pathogenic mechanism of cherubism.

Authors:  Noam Levaot; Oleksandr Voytyuk; Ioannis Dimitriou; Fabrice Sircoulomb; Arun Chandrakumar; Marcel Deckert; Paul M Krzyzanowski; Andrew Scotter; Shengqing Gu; Salima Janmohamed; Feng Cong; Paul D Simoncic; Yasuyoshi Ueki; Jose La Rose; Robert Rottapel
Journal:  Cell       Date:  2011-12-09       Impact factor: 41.582

6.  Neurofibromatosis presenting with a cherubism phenotype.

Authors:  C I van Capelle; P H G Hogeman; C J M van der Sijs-Bos; B G F Heggelman; B Idowu; P J Slootweg; A R M Wittkampf; A M Flanagan
Journal:  Eur J Pediatr       Date:  2006-11-21       Impact factor: 3.183

7.  SH3BP2 is an activator of NFAT activity and osteoclastogenesis.

Authors:  Steven A Lietman; Lihong Yin; Michael A Levine
Journal:  Biochem Biophys Res Commun       Date:  2008-04-25       Impact factor: 3.575

8.  NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism.

Authors:  Antonios O Aliprantis; Yasuyoshi Ueki; Rosalyn Sulyanto; Arnold Park; Kirsten S Sigrist; Sudarshana M Sharma; Michael C Ostrowski; Bjorn R Olsen; Laurie H Glimcher
Journal:  J Clin Invest       Date:  2008-10-09       Impact factor: 14.808

9.  Unusual Characteristics and Variable Expressivity in a Brazilian Family with Cherubism.

Authors:  Desirée Deconte; Elisa Pacheco Estima Correia; Géssica Haubert; Vinicius de Souza; Jamile Dutra Correia; Marcia Angelica Peter Maahs; Paulo Ricardo Gazzola Zen; Marilu Fiegenbaum; Rafael Fabiano Machado Rosa
Journal:  J Pediatr Genet       Date:  2020-02-28

Review 10.  Cherubism: best clinical practice.

Authors:  Maria E Papadaki; Steven A Lietman; Michael A Levine; Bjorn R Olsen; Leonard B Kaban; Ernst J Reichenberger
Journal:  Orphanet J Rare Dis       Date:  2012-05-24       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.